$10.09
4.18% today
Nasdaq, Apr 04, 08:48 pm CET
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

UroGen Pharma Ltd. Stock price

$10.53
+1.26 13.59% 1M
-1.85 14.94% 6M
-0.12 1.13% YTD
-3.13 22.91% 1Y
+1.96 22.87% 3Y
-7.84 42.68% 5Y
-3.45 24.68% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.67 5.98%
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

Key metrics

Market capitalization $485.37m
Enterprise Value $372.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.12
P/S ratio (TTM) P/S ratio 5.37
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 9.29%
Revenue (TTM) Revenue $90.40m
EBIT (operating result TTM) EBIT $-96.78m
Free Cash Flow (TTM) Free Cash Flow $-97.05m
Cash position $237.76m
EPS (TTM) EPS $-3.22
P/E forward negative
P/S forward 3.95
EV/Sales forward 3.03
Short interest 13.63%
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
86%
Hold
14%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
90 90
9% 9%
100%
- Direct Costs 8.88 8.88
5% 5%
10%
82 82
11% 11%
90%
- Selling and Administrative Expenses 120 120
31% 31%
133%
- Research and Development Expense 57 57
25% 25%
63%
-96 -96
50% 50%
-106%
- Depreciation and Amortization 1.19 1.19
30% 30%
1%
EBIT (Operating Income) EBIT -97 -97
48% 48%
-107%
Net Profit -127 -127
24% 24%
-140%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Neutral
Seeking Alpha
25 days ago
UroGen Pharma Ltd. (NASDAQ:URGN ) Q4 2024 - Earnings Conference Call March 10, 2025 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Michael Schmidt - Guggenheim Raghuram Selvaraju - H.
Neutral
Business Wire
25 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided an overview of recent developments. “2024 was a pivotal year for UroGen with achievements a...
Neutral
Business Wire
28 days ago
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 7 new employees in connection with their employment with UroGen. These new team members will support the ongoing commerciali...
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 235
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today